MALVERN, Pa., March 12, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or ...
DUBLIN, June 5, 2023 /PRNewswire/ -- Endo International plc (ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH, injection ...
DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for ...
Endo is taking its Peyronie's disease campaign from the vegetable aisle to the pool hall. Having initially relied on wonky veg to discuss the men’s health condition, the drugmaker has now brought four ...
Endo spent the better part of three and a half years on research to figure how best to market its Peyronie’s disease treatment Xiaflex. (Endo) () Endo once again hit the vegetable aisle to illustrate ...
September 17, 2009 — The US Food and Drug Administration (FDA)'s Arthritis Advisory Committee voted unanimously (12 to 0) yesterday to recommend approval of collagenase clostridium histolyticum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results